<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143282</url>
  </required_header>
  <id_info>
    <org_study_id>FWA00015574/6-01-2019/korany</org_study_id>
    <nct_id>NCT04143282</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment</brief_title>
  <official_title>Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hager salah el din</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the effect of metformin along with standard cancer treatment,
      and its effect on the prognosis of the metastatic breast in non-diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the role of metformin when combined with traditional metastatic breast cancer treatment in
      non-diabetic patients compared to diabetic patients who are not using metformin. In this
      randomized control study, there will be a demonstration either it is effective to suppress
      tumor burden or not through normal screening for tumor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The radiologic response rate</measure>
    <time_frame>3 months</time_frame>
    <description>The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) was used to evaluate the response to chemotherapy alone in case of control arm and chemotherapy plus metformin in case of drug arm for breast cancer with distant metastasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>the time period from the start of trial till death or end of follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>from the time between start of the trial and recurrence or disease progression, or end of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Growth like Factor -1 (IGF-1) at base line and after 3 cycle.</measure>
    <time_frame>3 months</time_frame>
    <description>measure blood Insulin Growth like Factor -1 (IGF-1) at the begining of trial then after 3 months at the end of 3 cycles (each cycle arround 28 days )</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non Diabetic metastatic breast cancer Patients will take metformin 1 gm. twice daily (Nathan 2009) along with standard chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non Diabetic metastatic breast cancer Patients will take standard chemotherapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus chemotherapy</intervention_name>
    <description>determine the effect of metformin along with standard chemotherapy</description>
    <arm_group_label>Metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>standard chemotherapy</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The non-diabetic patients will be included in the study if they meet the following
             criteria:

               1. Confirmed metastatic breast cancer (IV stage) radiologically or by clinical
                  evaluation receiving chemotherapy

               2. Age between 18- 70 years.

               3. Life expectancy at least 6 months

        Exclusion Criteria:

          -  The patients will be excluded from the study if they have the following criteria:

               1. Bad prognosis disease: Criteria defined as the following

                    -  If patient &gt;70 years

                    -  If patient has bad site metastasis (brain)

               2. Hypersensitivity for metformin: if happened patient will be treated as following

                  • Pheniramine Maleate 3 times daily for 7 days and Tablet Dexamethasone 1mg daily
                  in 2 divided doses for 5 days [16].

               3. Any condition associated with increased risk of metformin-associated lactic
                  acidosis (e.g., congestive heart failure defined as New York Heart Association
                  {NYHA} Class III or IV functional status; the history of acidosis of any type,
                  severe infections, kidney or liver disease, respiratory disease, seizures .

               4. Diabetic patients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>metastatic breast cancer female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ahmed a berry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Beni Suef University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ahmed h shaaban, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Beni Suef University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>hoda m rabea, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Beni Suef University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beni-Seuf University Hospital</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Hager salah el din</investigator_full_name>
    <investigator_title>pharmacist</investigator_title>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>non metastatic breast cancer</keyword>
  <keyword>non-diabetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>3 MONTHS</ipd_time_frame>
    <ipd_access_criteria>hager.salah@rocketmail.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

